Clinical Trial Update: Irinotecan Plus Anlotinib or Further in Combination With Penpulimab for Second-line Treatment of mCRC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating irinotecan plus anlotinib, with or without penpulimab, as second-line therapy for metastatic colorectal cancer; currently recr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• Irinotecan (Irinotecan)
• Penpulimab

Snippet

Sponsor: Fudan University | Conditions: Metastatic Colorectal Cancer | Phase 2 | Status: RECRUITING